Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children

Gene

Volumn 522, Issue 1, 2013, Pages 96-101

  Bellusci, Carolina P ^a   Rocco, Carlos ^a   Aulicino, Paula ^a   Mecikovsky, Debora ^a   Curras, Verónica ^b   Hegoburu, Soledad ^b   Bramuglia, Guillermo F ^b   Bologna, Rosa ^a   Sen, Luisa ^a   Mangano, Andrea ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

HAART; HIV 1 pediatric infection; Lopinavir; Single nucleotide polymorphism

Indexed keywords

AMPRENAVIR; CD4 ANTIGEN; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; RITONAVIR;

ADJUVANT THERAPY; ALLELE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG BLOOD LEVEL; FEMALE; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFANT; MALE; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROCEDURES; PROTEIN POLYMORPHISM; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HOMOZYGOTE; HUMANS; INFANT; LOPINAVIR; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84877005223     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.020     Document Type: Article

References (38)

1. Albermann N., et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 2005, 70(6):949-958.
2. Ameyaw M.M., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11(3):217-221.
3. Bellusci C.P., et al. MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission. AIDS 2010, 24(6):833-840.
4. Bernal M.L., Sinues B., Fanlo A., Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. 2003, 25(1):107-111.
5. Breilh D., et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004, 18(9):1305-1310.
6. Brumme Z.L., et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003, 17(2):201-208.
7. Cascorbi I., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001, 69(3):169-174.
8. Centers for Disease Control and Prevention (CDC) Revised classification system for human immunodeficiency virus (HIV) infection in children under 13years of age. MMWR Morb. Mortal. Wkly Rep. 1994, 43(RR-12):1-10.
9. Cianfriglia M., et al. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 2007, 4:17.
10. Curras V., et al. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. Pharmacology 2009, 83(1):59-66.
11. Droste J.A., Verweij-Van Wissen C.P., Burger D.M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther. Drug Monit. 2003, 25(3):393-399.
12. Estrela R.C., et al. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 2009, 10(2):311-318.
13. Fellay J., et al. Swiss HIV Cohort Study. Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359(9300):30-36.
14. Ford J., Hoggard P.G., Owen A., Khoo S.H., Back D.J. A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J. Immunol. Methods 2003, 274(1-2):129-137.
15. Furuno T., et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002, 12(7):529-534.
16. Geick A., Eichelbaum M., Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 2001, 276(18):14581-14587.
17. Haas D.W., et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J. Acquir. Immune Defic. Syndr. 2003, 34(3):295-298.
18. Hendrickson S.L., et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J. Acquir. Immune Defic. Syndr. 2008, 48(3):263-271.
19. Hoffmeyer S., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(7):3473-3478.
20. Kim R.B., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001, 70(2):189-199.
21. Komoto C., et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab. Pharmacokinet. 2006, 21(2):126-132.
22. la Porte C.J., et al. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clin. Pharmacol. Ther. 2007, 82(4):389-395.
23. Lamba J., Lamba V., Strom S., Venkataramanan R., Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos. 2008, 36(1):169-181.
24. Lee C.G., et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37(11):3594-3601.
25. Ma Q., et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007, 8(3):227-235.
26. Nasi M., et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003, 17(11):1696-1698.
27. Owen A., et al. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J. Virol. 2004, 78(21):12022-12029.
28. Parathyras J., Gebhardt S., Hillermann-Rebello R., Grobbelaar N., Venter M., Warnich L. A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J. Hum. Genet. 2009, 54(5):261-265.
29. Rakhmanina N.Y., et al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther. Drug Monit. 2011, 33(4):417-424.
30. Saitoh A., et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005, 19(4):371-380.
31. Schipani A., et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob. Agents Chemother. 2010, 54(12):5242-5250.
32. Siccardi M., et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C->T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis. 2008, 47(9):1222-1225.
33. Tanabe M., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 2001, 297(3):1137-1143.
34. van Luin M., Kuks P.F., Burger D.M. Use of therapeutic drug monitoring in HIV disease. Curr. Opin. HIV AIDS 2008, 3(3):266-271.
35. Verstuyft C., et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS 2005, 19(18):2127-2131.
36. Winzer R., et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 2003, 8(12):531-534.
37. Winzer R., et al. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. Ann. Clin. Microbiol. Antimicrob. 2005, 4:3.
38. Zhu D., et al. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir. Ther. 2004, 9(6):929-935.